Role of berberine nanoformulation in epilepsy: A novel therapeutic strategy.
Epilepsy Res
; 205: 107419, 2024 Sep.
Article
en En
| MEDLINE
| ID: mdl-39029440
ABSTRACT
The aim of the present study was to develop a novel formulation of berberine (BBR) and demonstrate its anti-seizure effect in pentylenetetrazole (PTZ) induced kindling model in rats. Nanoparticles of BBR were formulated using Poly Lactic-co-Glycolic Acid (PLGA) as a polymer. Emulsification and solvent evaporation technique was used. PTZ induced kindling model in male wistar rat was used to demonstrate the anti-seizure effect of nano-BBR. The particle size obtained for the final formulation was 242.8 ± 67.35â¯nm with a PDI of 0.140 ± 0.01. PLGA encapsulated BBR nanoparticles showed the % encapsulation efficiency of 87.33 ± 2.42â¯% and % drug loading of 48.47 ± 1.34â¯%. In-vitro drug release data showed sustained release of nano-BBR as compared to BBR. Kinetic study data showed increase in AUC of nano-BBR (35,429.46â¯h.ng/ml) as compared to BBR (28,211.07â¯h.ng/ml). Cmax for nano- BBR (2251.90â¯ng/ml) is approximately 1.6 times greater than BBR (1505.50â¯ng/ml). Nano- BBR has shown the significant effect on the seizure score. The PLGA encapsulated berberine nanoparticles were prepared by an innovative simple method and offers excellent potential as an antiepileptic agent.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Pentilenotetrazol
/
Berberina
/
Ratas Wistar
/
Modelos Animales de Enfermedad
/
Epilepsia
/
Nanopartículas
/
Copolímero de Ácido Poliláctico-Ácido Poliglicólico
/
Anticonvulsivantes
Límite:
Animals
Idioma:
En
Revista:
Epilepsy Res
Asunto de la revista:
CEREBRO
/
NEUROLOGIA
Año:
2024
Tipo del documento:
Article